Clinical Trial Update: To Assess Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus Patients [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating the safety of a fixed-dose combination of dapagliflozin and saxagliptin in Type 2 diabetes mellitus has completed, with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• FARXIGA (dapagliflozin)
• Onglyza (Saxagliptin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Phase 4 | Status: COMPLETED | Results posted: 2024-11-12